false 0001534525 0001534525 2024-02-12 2024-02-12 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2024-02-12 2024-02-12 0001534525 XBIO:PurchaseWarrantsMember 2024-02-12 2024-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

 

FORM 8-K

________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 12, 2024

________________________

 

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

Nevada   001-37937   45-2952962
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

945 Concord Street  
Framingham, Massachusetts 01701
(Address of principal executive offices) (Zip Code)

 

(781) 778-7720

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   XBIO   The Nasdaq Stock Market
Purchase Warrants   XBIOW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 7.01. Regulation FD Disclosure.

 

On February 12, 2024, Xenetic Biosciences, Inc. (the “Company”), posted a Virtual Investor event video with the Company’s Chief Scientific Officer, Curis Lockshin, PhD., discussing preclinical data from the Company’s DNase I oncology platform.

 

A link to the video may be found at https://www.virtualinvestorco.com/wtm-xbio-8k and is incorporated herein by reference.

 

The video link is furnished pursuant to this Item 7.01 and shall not be deemed filed in this or any other filing of the Company with the Securities and Exchange Commission, unless expressly incorporated by specific reference in any such filing.

 

 

 

 

 

 

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
   
  By: /s/ James Parslow                                        
Date: February 12, 2024 Name:   James Parslow
  Title:     Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
v3.24.0.1
Cover
Feb. 12, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 12, 2024
Entity File Number 001-37937
Entity Registrant Name Xenetic Biosciences, Inc.
Entity Central Index Key 0001534525
Entity Tax Identification Number 45-2952962
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 945 Concord Street
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01701
City Area Code (781)
Local Phone Number 778-7720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, $0.001 par value per share  
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol XBIO
Security Exchange Name NASDAQ
Purchase Warrants  
Title of 12(b) Security Purchase Warrants
Trading Symbol XBIOW
Security Exchange Name NASDAQ
Xenetic Biosciences (NASDAQ:XBIO)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Xenetic Biosciences.
Xenetic Biosciences (NASDAQ:XBIO)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Xenetic Biosciences.